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Abstract
Introduction: The aim of this study was to estimate serum fetuin-A levels in lean and obese women with polycystic ovary syndrome 
(PCOS) and to find possible relationships between fetuin-A, metabolic factors and androgens in these patients. 
Material and methods: In 25 lean (18–38 years, BMI 17.5–25.0 kg/m2) and 15 obese women (20–41 years, BMI 28.1–53.2 kg/m2) with PCOS, 
anthropometric indices and body composition were measured. Fasting serum fetuin-A, adiponectin, leptin, glucose, lipids, hsCRP, insulin, 
androgens and SHGB levels were estimated.
Results: There was no significant difference in serum fetuin-A levels between lean and obese patients: 0.54 ± 0.13 g/L and 0.60 ± 0.14 g/L, 
respectively. We noted a correlation between BMI and leptin levels (r = 0.88; p < 0.0001) and a nearly significant negative correlation 
between BMI and adiponectin levels (r = –0.53; p = 0.11) in all subjects. In lean patients, we found a correlation between fetuin-A levels 
and ALT activity (r = 0.44; p < 0.05). In all participants, fetuin-A correlated directly with DHEA-S levels (r = 0.44; p < 0.03).
Conclusions: Serum fetuin-A levels were similar in lean and obese women with PCOS. We found an association between fetuin-A levels 
and ALT activity in lean patients and between fetuin-A levels and DHEA-S in all women. The role of fetuin-A in the mechanisms of insu-
lin resistance, and its potential impact on androgenic hormones production in women with PCOS, need to be tested in further studies. 
(Endokrynol Pol 2014; 65 (5): 371–376)
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Streszczenie
Wstęp: Celem pracy było porównanie stężenia fetuiny A w surowicy u szczupłych i otyłych kobiet z zespołem policystycznych jajników 
(PCOS) oraz ocena, czy istnieją zależności między stężeniem tego białka a wskaźnikami metaboliczymi i androgenami w tej grupie chorych. 
Materiał i metody: U 25 szczupłych (wiek 18–38 lat, BMI 17,5–25,0 kg/m2) i 15 otyłych kobiet (wiek 20–41 lat, BMI 28,1–53,2 kg/m2) z PCOS 
dokonano pomiarów antropometrycznych i składu ciała, oraz określono na czczo stężenie fetuiny A, adiponektyny, leptyny, glukozy, 
lipidów, hsCRP, AlAT, insuliny, androgenów i SHBG. 
Wyniki: Między grupami kobiet szczupłych i otyłych nie stwierdzono różnicy w zakresie stężenia fetuiny A, które wynosiło odpowiednio 
0,54 ± 0,13 g/l i 0,60 ± 0,14 g/l. Wykazano silną korelację między BMI i leptyną (r = 0,88; p < 0,0001) i niemal znamienną ujemną korelację 
między BMI a adiponektyną (r = –0,53; p = 0,11) u wszystkich badanych kobiet. Wśród szczupłych uczestniczek wykazano korelację między 
stężeniem fetuiny A a aktywnością AlAT (r = 0,44; p < 0,05), zaś u wszystkich badanych korelację między stężeniem fetuiny A i DHEA-S 
(r = 0,44; p < 0,03)
Wnioski: Stężenie fetuiny A u szczupłych i otyłych kobiet było podobne. Wykazano zależność między stężeniem fetuiny A i aktywnością 
AlAT u szczupłych, oraz między stężeniem fetuiny A i DHEA-S u wszystkich badanych. Wyjaśnienie udziału fetuiny A w mechanizmach 
powstawania insulinooporności i ewentualnego wpływu na produkcję androgenów u kobiet z PCOS wymaga prowadzenia dalszych badań. 
(Endokrynol Pol 2014; 65 (5): 371–376)
Słowa kluczowe: zespół policystycznych jajników; fetuina A; otyłość; insuliooporność
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Introduction
Insulin resistance and hyperinsulinaemia represent 
substantial metabolic disturbances in women with 
polycystic ovary syndrome (PCOS) [1]. This syndrome 
affects 5–10% of women of reproductive age [2]. Liver-
derived fetuin-A, also known as alpha2-HS glycoprotein 
(AHSG) has been found to be one of the important fac-
tors involved in the pathogenesis of impaired insulin 
sensitivity. It is a natural inhibitor of insulin receptor 
autophosphorylation and tyrosine kinase activity in 
muscle and the liver, and thereby a blocker of insulin 
signal transduction [3]. Hence, AHSG is thought to 
play a significant role in weight gain, fat accumulation 
and the development of type 2 diabetes [4–6]. Fetuin-A 
knock-out mice did not exhibit insulin resistance and 
were protected against obesity on a high-fat diet [7]. 
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insulin-sensitivity increase and then restore the menses 
and ovulations [18].
Whether fetuin-A serum levels differ in lean and 
obese women with PCOS, and if AHSG contributes 
to insulin resistance in these patients, is so far still 
unknown.
The aim of our study was to compare serum fetuin-
A levels in lean and obese women with PCOS, and to 
examine whether there are any relationships between 
serum levels of AHSG, metabolic factors, markers of 
inflammation and androgens in these patients. 
Material and methods
We evaluated 25 lean women aged 18–38 years, mean 
25.0 ± 5.1 (x ± SD) with BMI 17.5 – 25.0 kg/m2 (20.9 ± 1.9), 
and 15 obese women aged 20-41 years (27.3 ± 5.9) with 
BMI 28.1-53.2 kg/m2 (36.2 ± 7.6, see Table I). In all subjects, 
PCOS was diagnosed according to the Rotterdam con-
sensus criteria: i.e. at least two of the following features: 
1) oligo- or anovulation, 2) clinical hyperandrogenaemia 
or/and elevated levels of androgenic hormones, and 3) 
polycystic ovaries in ultrasound imaging [19]. Other 
conditions with similar signs were excluded.
Clinical hyperandrogenaemia was defined as the 
presence of hirsutism and/or acne. Biochemical hyper-
androgenaemia was defined as serum testosterone levels 
greater than 3.1 nmol/L, dehydroepiandrosterone-sulfate 
levels (DHEA-S) greater than 2,000–4,100 ng/mL depend-
ing on age, or free androgen index (FAI) > 5.
act as a proadipogenic factor: in vitro studies revealed 
that fetuin-A stimulates fibroblasts and smooth muscle 
cell uptake of triglycerides and their incorporation into 
fatty acids [8]. However, it is still unknown whether 
similar effects occur in vivo. In humans, in a prospec-
tive case-cohort study, fetuin-A correlated positively 
with hs-CRP levels, promoted cytokine expression in 
monocytes, and suppressed the insulin-sensitising adi-
pokine adiponectin synthesis [9]. In well-functioning, 
community-living older persons, AHSG levels corre-
lated with the accumulation of visceral adipose tissue, 
with liver fat accumulation, and rose in patients with 
insulin resistance [10, 11]. Higher human fetuin-A 
levels have been found to be strongly associated with 
metabolic syndrome and atherogenic lipid profile, 
independently of the BMI [12]. It has been suggested 
that fetuin-A, similarly to the adipokines secreted from 
adipose tissue, may represent the first identified factor 
secreted from the liver (hepatokine) which modulates 
insulin signalling in target tissues [6]. 
Approximately 50% of women with polycystic ovary 
syndrome are overweight or obese and most of them 
have abdominal obesity that is associated not only with 
more severe insulin resistance but also with androgen 
excess and fertility disorders [13–15]. It is speculated 
that in PCOS, both abdominal adiposity and hyperan-
drogenism may be specific risk factors for developing 
atherothrombosis [16, 17]. It is presumed that changes 
in lifestyle and the use of proper medications could nor-
malise the endocrine system and metabolism through 
Table I. Baseline characteristics of lean (group 1) and obese (group 2) women with PCOS
Tabela I. Charakterystyka kobiet z zespołem policystycznych jajników z prawidłowym (grupa 1) oraz podwyższonym BMI 
(grupa 2)
Group 1 Group 2 P
N = Mean ± SD (range) N = Mean ± SD (range)
Age (years) 25 25.0 ± 5.1 (18.0–38.0) 15 27.3 ± 5.9 (20.0–41.0) NS
BMI [kg/m2] 25 20.8 ± 1.9 (17.5–25.0) 15 36.2 ± 7.6 (28.1–53.2)  < 0.0001
FM (%) 9 29.3 ± 8.1 (16.4–39.6) 11 47.5 ± 7.8 (36.4–56.5)  < 0.0001
FMt (%) 9 29.9 ± 9.9 (15.8–42.7) 11 49.7 ± 7.7 (37.5–60.1)  < 0.0001
TC [mmol/L] 24 4.5 ± 0.7 (3.3–6.1) 15 5.4 ± 1.0 (3.9–7.5)  < 0.004
LDL [mmol/L] 24 2.3 ± 0.6 (1.1–3.6) 15 3.4 ± 0.9( 2.2–5.3)  < 0.0001
HDL [mmol/L] 24 1.8 ± 0.3 (1.1–2.6) 15 1.2 ± 0.3 (0.8–1.8)  < 0.0001
TG [mmol/L] 24 0.74 ± 0.3 (0.4–1.6) 15 1.7 ± 0.9 (0.7–3.6)  < 0.0001
Glucose [mmol/L] 24 4.8 ± 0.7 (4.1–7.4) 15 5.0 ± 1.0 (4.0–8.4) NS
hsCRP [µg/L] 24 0.45 ± 0.3 (0.05–1.5) 13 8.07 ± 12.1 (0.4–39.6)  < 0.005
ALT [IU/mL] 24 14.3 ± 4.3 (7.0–25.0) 14 25.9 ± 11.6 (13.0–52.0)  < 0.0002
SBP [mm Hg] 25 115.0 ± 14.2 (90–140) 15 120.7 ± 11.9 (100–140) NS
DBP [mm Hg] 25 70.0 ± 11.9 (50–100) 15 74.0 ± 11.9 (60–90) NS
BMI — body mass index; FM — fat mass; FMt — fat mass of the trunk; TC — total cholesterol; LDL — low density lipoprotein cholesterol; HDL — high density lipoprotein 
cholesterol; TG — triglycerides; hsCRP — high sensitive C-reactive protein; ALT — alanine aminotransferase; SBP — systolic blood pressure; DBP — diastolic blood pressure
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Ovaries in USG were defined as polycystic when 
they included either ten or more follicles measuring 2–9 
mm in diameter or their volume was greater than 10 cm3.
Similar conditions: hyperprolactinemia (defined as 
serum prolactin levels greater than 25 ng/mL), Cush-
ing’s syndrome, nonclassical congenital adrenal hy-
perplasia (defined as serum 17-hydroxyprogesterone 
levels greater than 1.2 and 5.2 ng/mL in the follicular 
and luteal phase, respectively, or greater than 10 ng/mL 
in synacthen-stimulation test) were excluded. Also cur-
rent or previous (within the last three months) use of 
oral contraceptives and other hormonal drugs was an 
exclusion criterion from the study.
Subjects were studied after an overnight fast. As part 
of the physical examination, body height and weight 
mere measured, and then body mass index (BMI) was 
calculated. Blood was collected at about 8am for glucose, 
lipids (total cholesterol, low-density lipoprotein choles-
terol, high-density lipoprotein cholesterol and triglycer-
ides), high sensitive C-reactive protein (hsCRP), alanine 
aminotransferase (ALT), fetuin-A, leptin, adiponectin, 
insulin, LH, FSH, oestradiol, testosterone, dehydroe-
piandrosterone-sulfate, 17-hydroxyprogesterone and 
sex hormone-binding globulin (SHBG), through an i.v. 
catheter placed in the forearm. Free androgen index (FAI) 
was calculated as testosterone (nmol/L)/SHBG (nmol/L) 
levels. Homeostasis Model of Assessment - Insulin 
Resistance (HOMA) was calculated by the formula: 
fasting plasma insulin (microinternational units per 
millilitre) x fasting plasma glucose (millimoles per 
litre)/22.4.
Subjects were considered as insulin resistant when 
HOMA index was > 2.5. All subjects underwent 
transvaginal ultrasonography (TV-USG) and USG of 
abdomen (to estimate liver echogenity and to exclude 
adrenal pathology). At the end of the investigation, 
body composition by DEXA was determined. The 
same two operators performed all TV-USG and DEXA 
measurements, respectively. 
The local ethical committee approved the study, and 
informed consent was obtained from all participants.
Assays
Glucose was measured with a glucose hexokinase 
reagent set with sensitivity of 2.16 mg/dL. An en-
zymatic colorimetric method was used to measure 
total cholesterol in the presence of cholesterol oxi-
dase and esterase. The sensitivity was 0.116 mg/dL. 
HDL-cholesterol was measured with an enzymatic 
colorimetric method; sensitivity was 3 mg/dL. Tri-
glycerides were also measured with an enzymatic 
colorimetric method with sensitivity of 0.85 mg/dL. 
All mentioned biochemical measurements were per-
formed using a Roche Cobas Integra 400 chemistry 
analyser (Roche Diagnostics). Insulin was measured 
by the immunoradiometric method (Insulin IRMA — 
Immunotech SA, France); sensitivity was 2.0 mIU/mL. 
Fetuin-A was measured in serum diluted 10,000 times, 
by Human Fetuin-A ELISA kit, (Epitope Diagnostics 
Inc, San Diego, CA, USA). Leptin was measured 
by RIA (Linco Res. Inc, USA), using rabbit antibodies 
against human leptin. The sensitivity for this assay was 
0.5 ng/mL. Adiponectin was measured by RIA method 
(Millipore, MI, USA, human adiponectin), detection 
limit 1 ng/mL. LH and FSH were measured by an im-
munochemiluminescence method with IMMULITE 2000 
(Siemens Healthcare Diagnostics, Inc). Oestradiol was 
measured with the same IMMULITE 2000 analyser, 
with sensitivity of 15 pg/mL. Total testosterone was 
measured by an immunochemiluminescence method 
with Architect iSR 2000 (Abbot Diagnostics Division, 
Abbot Park, IL, USA); sensitivity was 0.08 ng/mL. 
Results were then multiplied by a factor of 3.46 to 
obtain nmol/L. Dehydroepiandrosterone-sulfate 
was measured by an immunochemiluminescence 
method with IMMULITE 2000 (Siemens Healthcare 
Diagnostics, Inc); sensitivity of this method was 
30 ng/mL. 17-hydroxyprogesterone was measured 
by 17OH-RIA-CT Kit (DIAsource ImmunoAssays SA, 
Belgium); detection limit: 0.02 ng/mL. SHBG was 
measured by IRMA method (Orion Diagnostics Oy, 
Finland); detection limit: 1.3 nmol/L. 
Body mass index was calculated as body weight 
(kg)/height (m2). Subjects with BMI between 25 and 
30 kg/m2 were considered as overweight, whereas 
subjects with BMI between 30 and 40 kg/m2 were 
considered as obese, and with BMI above 40 kg/m2 
as morbidly obese.
To perform measurements of body composition we 
used a Lunar Prodigy (GE Lunar, Madison, WI, USA) de-
vice, which was calibrated each day with a standardised 
phantom and serviced regularly. The coefficient of vari-
ation for measurements with this method is about 2%.
Statistical analysis
All data is presented as the mean ± SD. The normal-
ity of the distribution of variables was verified with 
a Kolmogorov-Smirnov test. To examine bivariate 
relationships between data, Pearson correlation or 
Spearman rank analyses were used. Comparisons 
between groups with normal distribution of the data 
were performed by unpaired Student’s t-test, in other 
cases comparisons were performed by Kolmogorov-
Smirnov test for two samples. For all analyses, a two-
tailed P ≤ 0.05 was considered to indicate statistical 
significance. All calculations were performed with 
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Results
Baseline characteristics of lean (group 1) and obese (group 
2) subjects are shown in Table I. In group 2, four patients 
(26.6%) were overweight and 11 were obese, of whom 
five (33.3%) were considered as morbidly obese. All of the 
obese subjects had increased fat mass of the trunk. Only 
one woman (in group 1) was hypertensive, with increased 
diastolic blood pressure. In 12 women (including five in 
group 1), hypercholesterolemia , was foundand also in 
12 (including two in group 1) hypertriglycerydemia was 
found. Lean women had lower serum lipids, hsCRP levels 
and ALP activity than obese patients. 
Table II presents hormonal results of our patients. 
Twenty one subjects (84.0%) in group 1 and 13 (86.6%) 
in group 2 were hyperandrogenic. Four, all in group 2 
(26.6%), had elevated fasting serum insulin levels, and 
six (including one in group 1) were considered as insulin 
resistant. Lean patients had lower fasting insulin and 
leptin levels, HOMA index, and higher adiponectin 
levels than obese patients. There was no significant 
difference in serum fetuin-A levels between lean and 
obese subjects. We found significantly lower FAI and 
higher SHBG levels in lean compared to obese women. 
We noted a strong correlation between BMI and 
serum leptin levels (r = 0.88; p < 0.0001; Fig. 1) and a 
nearly significant negative correlation between BMI 
and serum adiponectin levels (r = –0.53; p = 0.11) in 
all subjects. In both groups estimated separately, similar 
correlations were found.
Among lean patients (group 1), we found a cor-
relation between serum fetuin-A levels (g/L) and ALT 
activity (IU/mL), (r = 0.44; p < 0.05; Fig. 2)
Table II. Hormonal results of our patients
Tabela II. Wyniki badań hormonalnych badanych kobiet
Group 1 Group 2 P
N = Mean ± SD (range) N = Mean ± SD (range)
Insulin [µIU/mL] 22 3.5 ± 3.1 (1.0–13.0) 14 10.8 ± 8.5 (2.0–27.0)  < 0.0001
HOMA 22 0.8 ± 0.7 (0.2–3.3) 14 2.4 ± 1.8 (0.4–6.2)  < 0.001
Leptin [ng/mL] 17 15.1 ± 7.2 (3.4–27.5) 12 42.3 ± 26.8 (11.4–95.2)  < 0.0001
Adiponectin [µg/mL] 19 14.1 ± 6.8 (3.5–31.8) 9 5.9 ± 2.8 (3.0–11.7) 0.024
Fetuin-A [g/L] 21 0.54 ± 0.13 (0.4–09) 11 0.6 ± 0.14 (0.4–0.9) NS
Testosterone [mmol/L] 24 2.4 ± 1,3 (0.6–5.6) 15 2.8 ± 1.6 (0.6–5.3) NS
DHEA-S [ng/mL] 24 3,123.7 ± 1,543 (749–6,740) 15 2,553.1 ± 1,024 (1,180–4,490) NS
FAI 21 5. 7 ± 5.2 (1.0–253) 14 11.6 ± 6.7 (2.6–26.2)  < 0.0001
LH/FSH 24 2.1 ± 1.1 (0.3–4.0) 15 1.7 ± 0.8 (0.6–3.5) NS
Oestradiol [pg/mL] 24 49.2 ± 43.4 (21.9–233.0) 15 47.6 ± 22.6 (15.0–84.4) NS
SHBG [nmol/L] 21 63.3 ± 44.9 (21.4–218.0) 15 29.4 ± 11.2 (17.0–55.0)  < 0.001
HOMA — homeostatic model assessment; DHEA-S — dehydroepiandrosterone-sulfate; FAI — free androgen index; LH — luteinising hormone; FSH — follicle stimulating 
hormone; TSH — thyroid stimulating hormone; SHBG — sex hormone-binding globulin
Figure 1. Correlation between BMI (kg/m2) and serum leptin 
(µg/mL) levels in all studied women 
Rycina 1. Korelacja między BMI (kg/m2) a stężeniem leptyny 
w surowicy (µg/ml) wśród wszystkich badanych kobiet
Figure 2. Correlation between serum fetuin-A levels and ALT 
activity in lean women with polycystic ovary syndrome 
Rycina 2. Korelacja między stężeniem fetuiny A i aktywnością AlAT 
w surowicy w grupie kobiet z prawidłowym BMI
375












In all studied women, serum fetuin A levels (g/L) 
correlated directly with DHEA-S levels (ng/mL), 
(r = 0.44; p < 0.03; Fig. 3)
Discussion
To the best of our knowledge, this is the first study to 
compare fetuin-A levels in lean and obese women with 
PCOS. We demonstrated that levels of AHSG are similar 
in both studied groups. 
The reason we studied liver-derived fetuin-A in 
women with PCOS was the previous observation that 
this protein may play a significant role in mechanisms 
that regulate postprandial glucose disposal, insulin 
sensitivity, weight gain and fat accumulation [4–6]. 
Especially because, as in animal and human studies 
the inhibitory function of fetuin-A on insulin recep-
tor tyrosine kinase in the muscle and in the liver has 
been proved [20, 21] AHSG may be considered as an 
important link between obesity and insulin resistance. 
On the other hand, decreased insulin sensitivity and 
subsequent hyperinsulinaemia, in PCOS more severe 
than expected on the basis of body weight, represent 
crucial metabolic disturbances in the majority of obese 
as well as of lean women with PCOS [22, 23]. Moreover, 
it is postulated that obesity in women with PCOS is 
associated not only with more severe insulin resist-
ance but also with hyperandrogenemia and fertility 
disorders [24]. Also investigations of the genetic aspects 
of polycystic ovary syndrome have pointed to the sig-
nificance of metabolic disturbances. It is apparent that 
some specific insulin and its receptor gene alleles and 
genotypes may determine the predisposition to ano-
vulatory PCOS and to the concomitant risk of diabetes 
development. Significant alterations have been found 
in the expression of genes responsible for androgen 
production and of oestrogen receptor in granulose and 
theca cells potentially related to abnormal follicular 
development [25]. 
Our finding, that fetuin-A levels in lean and obese 
women with polycystic ovary syndrome are not dif-
ferent, is rather unexpected. A few other human stud-
ies, that did not involve women with PCOS, found 
higher levels of AHSG in obese subjects with metabolic 
disturbances compared to lean individuals. In obese 
children, initially elevated fetuin-A levels decreased 
during exercise- and diet-induced weight loss [27]. In 
patients with morbid obesity, fetuin-A was markedly 
increased and significantly declined after weight loss 
resulting from bariatric surgery. This fall was related 
to changes in insulin resistance but not directly to BMI 
[27]. Our lean and obese patients did not differ in insulin 
resistance estimated by HOMA. Our results should be 
re-evaluated in future studies. In two recently published 
independent trials, there was divergent data on serum 
fetuin-A levels in women with PCOS. In the paper by 
Abali et al. [28], mean serum fetuin-A concentrations 
were considerably elevated compared to healthy con-
trols, whereas in the study by Gulhan et al. [29], there 
was no difference between women with PCOS and 
healthy subjects with regard to fetuin-A levels. Probably, 
all these discrepancies may be related to differences in 
age, BMI, liver fatness, level of insulin resistance and 
other yet undefined metabolic factors.
In our lean patients, we found an association 
between serum fetuin-A levels and alanine ami-
notransferase activity. ALS is considered to be a weak 
surrogate marker of liver fatness, and in combination 
with ultrasound imaging enables the diagnosis of non-
alcoholic fatty liver disease (NAFLD) [30]. We did not 
measure directly fat content in the liver in this study. 
However, our finding may be intelligible because 
NAFLD is known to be strongly associated with insulin 
resistance and is regarded as a hepatic manifestation of 
metabolic syndrome [31]. Similarly, one may consider 
polycystic ovary syndrome as the ovarian manifestation 
of metabolic syndrome. Our findings are in accordance 
with the observations of Stefan et al. [5] in healthy 
Caucasians, and may support the hypothesis that fat 
accumulation in the liver may result in an increased 
secretion of AHSG. 
We noted a significant correlation between serum 
fetuin-A and DHEA-S levels in our subjects. DHEA-S, 
the main adrenal androgen, is the most abundant 
among circulating androgen hormones. On the other 
hand, in women with PCOS, obesity and subsequent 
hyperinsulinaemia are regarded as meaningful factors 
that contribute to androgen excess [32]. It could be that 
fetuin-A is a factor that promotes insulin resistance, and 
Figure 3. Correlation between serum fetuin-A and DHEA-S levels 
in women with PCOS
Rycina 3. Korelacja między stężeniem fetuiny A i DHEA-S 
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in consequence hyperinsulinaemia may be associated 
with increased androgen production in women with 
PCOS, at least in adrenals. We could not demonstrate 
a similar correlation for testosterone and FAI. In the case 
of FAI, the impact of obesity on hepatic SHBG produc-
tion and therefore on its serum levels should be taken 
into account additionally.
Several limitations should be considered when our 
results are interpreted. Firstly, it includes a relatively 
small number of studied patients, especially in the 
group of obese women. Secondly, we did not adjust 
for additional factors and biochemical variables, so 
we cannot be sure that any unmeasured covariates 
may have influenced our observations. Thirdly, our 
results are based on single measurements of fetuin-A. 
This might have introduced random measurement er-
rors in determining biochemical variables. However, 
if anything, such a random error would bias results 
toward the null. As already discussed, the relationships 
between fetuin-A and ALS activity were surprisingly 
evident only in lean patients. Future prospective studies 
should evaluate whether these results could refer also 
to obese women with PCOS. Finally, our study subjects 
were mostly young women, and so our results may not 
be generalisable to older patients with PCOS. 
In conclusion, we demonstrated that serum fetuin-A 
levels are similar in lean and obese women with PCOS. 
We found an association between fetuin-A levels and 
ALS activity in lean patients, and between fetuin-A 
levels and DHEA-S in all women. The role of fetuin-A 
in the mechanisms of insulin resistance and its potential 
impact on androgenic hormones production in women 
with PCOS need to be tested in further studies. 
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